Literature DB >> 7562053

Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide.

G C Scott1, D A Meier, C Z Dickinson.   

Abstract

A 49-yr-old white woman with diffuse sclerosing variant of papillary carcinoma of the thyroid revealed abnormal [18F]FDG accumulation within cervical lymph node metastases prior to thyroidectomy. The abnormal cervical foci of glucose metabolism corresponded to similar areas of abnormal [99mTc]pertechnetate and radioiodine accumulation on presurgical scans. The primary thyroid tumor within the thyroid gland was not delineated as a focal defect on any of the three imaging studies. The relative thyroid-to-background soft-tissue ratio in the [18F]FDG study, however, appeared higher than usual. As with 131I and [99mTc]pertechnetate, this case demonstrates that [18F]FDG PET can detect cervical lymph node metastases in the preoperative thyroid cancer patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562053

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases.

Authors:  Lester D R Thompson; Jacqueline A Wieneke; Clara S Heffess
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  High uptake in schneiderian papillomas of the maxillary sinus on positron-emission tomography using fluorodeoxyglucose.

Authors:  F Y Lin; E M Genden; W L Lawson; P Som; L Kostakoglu
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-03       Impact factor: 3.825

Review 3.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

4.  Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?

Authors:  Michael Zoller; Susanne Kohlfuerst; Isabel Igerc; Ewald Kresnik; Hans-Jürgen Gallowitsch; Iris Gomez; Peter Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-14       Impact factor: 9.236

5.  A hand-held beta imaging probe for FDG.

Authors:  Bipin Singh; Brendan C Stack; Samta Thacker; Valeriy Gaysinskiy; Twyla Bartel; Val Lowe; Steven Cool; Gerald Entine; Vivek Nagarkar
Journal:  Ann Nucl Med       Date:  2012-12-11       Impact factor: 2.668

6.  Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Andrea Frilling; Hilmar Kühl; Stefan P Müller; Walter Jentzen; Andreas Bockisch; Gerald Antoch
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

7.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.

Authors:  F Grünwald; A Schomburg; H Bender; E Klemm; C Menzel; T Bultmann; H Palmedo; J Ruhlmann; B Kozak; H J Biersack
Journal:  Eur J Nucl Med       Date:  1996-03

8.  Diagnostic accuracy of single-source dual-energy computed tomography and ultrasonography for detection of lateral cervical lymph node metastases of papillary thyroid carcinoma.

Authors:  Lin Li; Sai-Nan Cheng; Yan-Feng Zhao; Xiao-Yi Wang; De-Hong Luo; Yong Wang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

9.  99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study.

Authors:  Min Liu; Li Chai; Qiong Luo; Maomei Ruan; Lingxiao Cheng; Zhongwei Lv; Libo Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

Review 10.  Primary accessory thyroid carcinoma with negative 99mTcO4- SPECT/CTimaging: a case report and literature review.

Authors:  Yibo Ma; Feng Qian; Jianfeng Wang; Yanping Liu; Shuiqing Liu
Journal:  J Int Med Res       Date:  2019-07-15       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.